Sorry, mate. I don't think I answered you correctly.
Biomarkers: Something like tumor DNA damage markers for lead in single agent and combination.
Clinical Responses: Complete and partial responses, and progression free survival.
Clinical responses can be correlated with biomarker activity to determine synergism. Comparing clinical responses for the combination can be made to known populations with similar demographics who have received single-agent Dox at equivalent dosing. There should be a fair amount of information available for Doxorubicin to compare the combination to. For example, here is a paper that evaluated single-agent doxorubicin in anthracycline naive second-line metastatic breast cancer patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150384/pdf/brjcancer00088-0203.pdf
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-142
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |